Rezolute, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RZLT research report →
Companywww.rezolutebio.com
Rezolute, Inc. , a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
- CEO
- Nevan Charles Elam
- IPO
- 2013
- Employees
- 64
- HQ
- Redwood City, CA, US
Price Chart
Valuation
- Market Cap
- $310.54M
- P/E
- -4.12
- P/S
- 0.00
- P/B
- 2.87
- EV/EBITDA
- -3.51
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -58.82%
- ROIC
- -73.68%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-74,412,000 · -8.70%
- EPS
- $-0.98 · 26.32%
- Op Income
- $-79,894,000
- FCF YoY
- -20.41%
Performance & Tape
- 52W High
- $11.46
- 52W Low
- $1.07
- 50D MA
- $3.15
- 200D MA
- $5.49
- Beta
- 0.67
- Avg Volume
- 2.16M
Get TickerSpark's AI analysis on RZLT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 30, 26 | Evans Daron | buy | 10,000 |
| Mar 2, 26 | ROBERTS BRIAN KENNETH | other | 11,439 |
| Mar 2, 26 | Evans Daron | other | 11,438 |
| Mar 2, 26 | Elam Nevan C | other | 27,618 |
| Dec 16, 25 | Hogenhuis Wladimir | buy | 5,650 |
| Dec 16, 25 | ROBERTS BRIAN KENNETH | buy | 28,000 |
| Dec 15, 25 | Evans Daron | buy | 40,000 |
| Dec 15, 25 | Evans Daron | buy | 2,500 |
| Dec 15, 25 | Evans Daron | buy | 2,500 |
| Dec 15, 25 | Elam Nevan C | buy | 32,000 |
Our RZLT Coverage
We haven't published any research on RZLT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RZLT Report →